Canada's drug price watchdog issues decision in acne drug case
/EINPresswire.com/ -- OTTAWA, ONTARIO--(Marketwired - Dec 21, 2016) - Patented Medicine Prices Review Board
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued an Order on December 19, 2016 relating to the medicines Differin and Differin XP, manufactured and marketed in Canada by Galderma Canada Inc. (Galderma). The Hearing Panel found that one of the three patents at issue in the proceedings pertains to Differin and ordered Galderma to provide PMPRB staff with pricing and sales information required by section 80 of the Patent Act and the Patented Medicines Regulations with respect to that medicine for the period between January 1, 2010 and March 14, 2016. The Hearing Panel dismissed PMPRB staff's application with respect to the other two patents at issue.
Quick Facts
- The Patented Medicine Prices Review Board is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive, and provides stakeholders with price, cost, and utilization information to help them make timely and knowledgeable drug pricing, purchasing, and reimbursement decisions.
- Patentees must file price and sales information with the Patented Medicine Prices Review Board at introduction, and twice a year afterward, for each strength of each dosage form of each patented medicine sold in Canada.
- Patented Medicine Prices Review Board staff review the prices patentees charge for each individual patented drug product sold in Canadian markets on an ongoing basis to ensure their prices are not excessive.
- If the Patented Medicine Prices Review Board (PMPRB) Hearing Panel finds a patentee to be in breach of its reporting requirements, the Panel may order the patentee to provide the PMPRB with the required pricing and sales information.
Related Documents
• Board Order (PDF - 311 kb)
Associated Links
• Patent Act (Justice Canada)
• Patented Medicines Regulations (Justice Canada)
• Status of Ongoing Proceedings (Patented Medicine Prices Review Board)
Follow us on Twitter: @PMPRB_CEPMB
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Sofie.McCoy-Astell@pmprb-cepmb.gc.ca
TTY (telecommunications device
for the hearing impaired)
613-957-4373
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
